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Introduction
While the term epigenetics is often used loosely, and 
sometimes in rather diﬀ  erent ways, the term is generally 
considered to encompass changes in DNA methylation, 
histone modiﬁ  cations, miRNA expression, and nucleo-
some positioning and higher order chromatin as epi  genetic 
changes aﬀ  ecting gene regulation. Epigenetics was deﬁ  ned 
as a discipline more than 50 years ago, by CH 
Waddington, and originally described changes in the 
development of organisms that could not be explained by 
changes in DNA. Subsequently it became clear that 
epigenetic modiﬁ  cations play important roles in diseases, 
including breast cancer. Th   ere is thus a pressing need to 
understand the functional genome; that is, the changes 
deﬁ  ned by regulatory mechanisms overlaying the genetic 
structure.
Over the past few years there has been an explosion in 
studies of epigenetics in breast cancer, reﬂ  ected by the 
exponential increase of published manuscripts (Figure 1). 
A PubMed search for the keywords ‘epigenetic’ and 
‘breast cancer’ reveals that the ﬁ  rst publication was in 
1983. Progress was slow until approximately 10 years ago 
when the number of studies started to steadily increase, 
at least in part fueled by improved technologies. In the 
present review, we focus on recent advances in the 
understanding of histone methylation and demethylation, 
a relatively new area with promise for clinical translation. 
We also review recent studies that have utilized genome-
wide technologies for the study of DNA methylation. 
Much progress has been made in the characterization of 
noncoding RNAs, and the eﬀ   ect of higher order 
chromatin structure on gene expression in breast cancer; 
however, these discoveries lie outside the scope of our 
review.
Finally, we also discuss the relatively slow translation of 
results from the epigenetic ﬁ  eld into the clinic. Although 
there has been a dramatic increase of research into the 
epigenetics of breast cancer and milestone discoveries 
have undoubtedly been made, the application of such 
ﬁ  ndings into the clinical setting has been slow. Th   is is in 
contrast to other areas – for example, proﬁ  ling of gene 
expression, where we have witnessed a revolution in the 
past 4 to 6  years, especially in the translation of the 
results into the development of US Food and Drug 
Administration-approved multigene prognostic assays. 
Why have we not yet seen any predictive/prognostic tests 
that involve the characterization of epigenetic changes? 
In a similar way, although a number of drugs targeting 
epigenetic changes have been tested, at this time no 
epigenetic drug has received US Food and Drug 
Administration approval in breast cancer treatment. Is 
this a result from a slower development of techniques 
used for epigenetic analysis? Or are there additional 
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© 2011 BioMed Central Ltdobstacles? In the present review article we discuss some 
barriers to more rapid translation of epigenetic studies in 
breast tumors into clinical practice, and discuss the 
eﬀ   orts by the Epigenome Project and Th  e Cancer 
Genome Atlas (TCGA) that are expected to bring 
dramatic progress in the near future.
Acetylation and methylation of histones in breast 
cancer
For many years it has been known that post-translational 
modiﬁ  cations of histone tails determine, in part, which 
regions of the genome are in an open and thus trans  crip-
tionally active conformation, and which are closed and 
thus transcriptionally inactive. Th  e  modiﬁ  cations of his-
tone tails include acetylation, methylation, ubiquitylation, 
phosphorylation, sumoylation, and ribosylation, each of 
which can signiﬁ  cantly aﬀ  ect the expression of genes [1]. 
Th  e most studied histone modiﬁ   cations are histone 
acetyla  tion/deacetylation, and more recently methyla  tion/
demethylation. In breast cancer, abnormal histone 
modiﬁ   cation in combination with DNA hypermethy-
lation is frequently associated with epigenetic silencing of 
tumor suppressor genes and genomic instability [2,3]. 
Understanding the mechanisms of dysregulation of 
histone tail post-translational modiﬁ   cations and their 
contribution to breast tumorigenesis is critically impor-
tant in the development of novel targeted therapy for 
breast cancer patients.
Inhibition of histone deacetylases as a therapeutic 
approach in breast cancer
Th   e dynamic nature of histone acetylation is determined 
by the counterbalancing activity of histone acetyl  trans-
ferases and histone deacetylases (HDACs). Th  e HDAC 
family is divided into zinc-dependent enzymes (classes I, 
IIa, IIb, and IV, of which there are 11 subtype enzymes) 
and zinc-independent enzymes (class III, also called 
sirtuins), which require NAD+ for their catalytic activity 
[4]. Over the past decade, a number of HDAC inhibitors 
have been rationally designed and synthesized based on 
their chemical structures and divided into four groups: 
hydroxamic acids, cyclic tetrapeptides, short-chain fatty 
acids, and benzamides [5]. Most of the HDAC inhibitors 
developed so far are nonselective, and among the most 
potent inhibitors are those that have been designed to 
target primarily the zinc cofactor at the active site of the 
HDACs and to exhibit their eﬀ  ects in the nanomolar or 
micromolar range [6,7]. Some of these HDAC inhibitors 
were shown to change the chromatin structure and cause 
re-expression of aberrantly silenced genes, which in turn 
is associated with growth inhibition and apoptosis in 
cancer cells [8,9]. In estrogen receptor (ER)-negative 
breast cancer cells, inhibition of HDAC activity by 
speciﬁ   c HDAC inhibitors reactivates ERα and proges-
terone receptor (PR) gene expression, which are known 
to be aberrantly silenced [10-14]. Pruitt and colleagues 
demonstrated that inhibition of class III HDAC SIRT1 
using a pharmacologic inhibitor, splitomicin, or siRNA 
reactivates epigenetically silenced SFRP1,  SFRP2, E-
cadherin, and CRBP1 genes in human breast cancer cells 
[15].
Th   e study of HDAC inhibitors is moving rapidly into a 
new stage of development that has now started to pro-
duce encouraging results in the clinic, particularly in the 
ﬁ  eld of cancer therapy. Vorinostat (SAHA) and romidep-
sin (FK228) have already been approved by the US Food 
and Drug Administration for the clinical treatment of 
cutaneous T-cell lymphoma. Vorinostat is currently 
under evaluation in several phase II trials in breast cancer 
[16,17], including combination therapy of vorinostat with 
standard cytotoxic agents (for example, paclitaxel), endo-
crine therapy (tamoxifen), or novel targeted therapy 
(trastuzumab, bevacizumab) [3,16,17]. Other HDAC 
inhibitors such as MS-275 (entinostat) and LBH-589 
(panobinostat) are in phase I/II studies in combination 
with other agents, such as trastuzumab, in women with 
metastatic HER2-positive breast cancer [16].
In addition, increasing evidence suggests that combi-
nation treatment with inhibitors of HDAC and DNA 
methyltransferase (DNMT) results in synergy at clinically 
tolerable doses that may translate not only into changes 
in methylation but also to disease response. Preclinical 
studies of HDAC inhibitors in combination with DNMT 
inhibitors have shown superior re-expression of silenced 
genes and increased apoptosis in colon/lung cancer cell 
lines [18], reduced tumorigenesis in lung cancer models 
[19,20], superior ER re-expression compared with HDAC 
inhibitor alone in breast cancer cell lines [12], and res  tora  tion 
Figure 1. Increased rate of publication in the area of epigenetics 
and breast cancer. Data are derived from a PubMed citation analysis 
searching for ‘breast cancer’ and ‘epigenetics’, and are approximate 
refl  ections of the number of epigenetic studies in the breast cancer 
area.
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Page 2 of 11of tamoxifen responsiveness [13,21]. In a phase I clinical 
trial of phenylbutyrate in combination with the DNMT 
inhibitor 5-azacitidine in myelodysplasia, res  ponse was 
highly correlated with reversal of aberrantly methylated 
genes [22]. In another phase I trial in non  small-cell lung 
cancer, the combination of a DNMT inhibitor and an 
HDAC inhibitor was safe and tolerable, and was 
associated with clinical activity [23].
An ongoing phase II trial is testing the HDAC inhibitor 
entinostat (also known as SNDX-275 and MS-275), in 
combination with 5-azacitidine, in patients with hormone-
refractory or triple-negative metastatic breast cancer. Th  e 
primary endpoint will be the objective response rate; 
secondary endpoints will be progression-free survival, 
overall survival, and clinical beneﬁ  t rate, as well as safety 
and tolerability. Other analyses will include the pharma-
co  kinetics of 5-azacitidine and entinostat, cytidine 
deaminase activity, pharmacogenetics, and baseline and 
change in gene methylation in circulating DNA prior to/
following combination therapy (quantitative multiplex 
methylation speciﬁ   c PCR). Th  e study will also aim to 
evaluate baseline and change in malignant tissue via 
mandatory biopsies prior to/following combination 
therapy of gene methylation of candidate genes (by 
quantitative methylation speciﬁ  c PCR) and of genome-
wide methylome, coupled with the study of candidate 
gene re-expression (RT-PCR). We are at a critical turning 
point, because results from these critical studies will 
guide future trials with HDAC inhibitors.
Targeting histone lysine methylation and demethylation in 
breast cancer
Histone lysine methylation is a reversible process, 
dynami  cally regulated by both lysine methyltransferases 
and demethylases (Figure 2). In general, methylation of 
histone H3 lysine 4 (H3K4me), H3K36, or H3K79 is 
associated with active transcription, whereas methylation 
of H3K9, H3K27, or H4K20 is associated with gene 
silenc  ing [1]. Histone methylation is regulated in breast 
cancer in an even more complicated manner than histone 
acetylation via a large number of chromosomal remodel-
ing regulatory complexes.
Modiﬁ  cation of H3K4 methylation is catalyzed by the 
Trithorax group of histone methyltransferases, including 
SET1 and MLL [24]. Th   e activity of Trithorax proteins is 
balanced by the opposing eﬀ  ects of the Polycomb group 
factors, another important histone methyltransferase 
family that mediates methylation usually associated with 
epigenetic gene silencing [25]. Polycomb group proteins 
form at least four diﬀ   erent complexes, including the 
maintenance complex PRC1 – composed of RING, HPC, 
HPH, and BMI1 – and three diﬀ  erent  initiation 
complexes, PRC2 through PRC4, which are formed by 
core component of zeste homolog 2 (EZH2), suppressor 
of zeste 12 (SUZ12), and Nurf-55 [26,27]. EZH2 is a 
highly conserved histone methyltransferase that speciﬁ  -
cally targets H3K27 and functions as transcriptional 
repressor [28]. Tissue microarray analysis of breast 
cancers identiﬁ   ed consistent overexpression of EZH2, 
which was strongly associated with tumor aggressiveness 
[29]. Studies from several groups demonstrated that ex-
pres  sion of EZH2 is signiﬁ    cantly associated with increased 
proliferation and other features of aggressive breast 
cancer, such as p53 altera  tions, c-erbB-2 expres  sion, 
markers of the basal-like subtype, and glomeruloid micro-
vascular proliferation [30,31]. Finally, in a recent report by 
Chang and colleagues, EZH2 was shown to repress DNA 
repair in breast-tumor-initiating cells, potentially leading 
to expansion of stem-cell-like cells, and ﬁ  nally to breast 
cancer progression [32]. Collectively, these results 
suggest that EZH2 might function as a prognostic bio-
marker in breast cancer, and might also be a promising 
treatment target.
Histone lysine-speciﬁ   c demethylase 1 (LSD1, also 
known as BHC110, AOF2, or KDM1) is the ﬁ  rst identiﬁ  ed 
histone lysine demethylase capable of speciﬁ  cally  de-
methy  lating monoethylated and dimethylated lysine 4 of 
histone H3 (H3K4me1 and H3K4me2) [33,34]. Th  e dis-
covery of LSD1 has revolutionized the concept of histone 
methylation as a dynamically regulated process under 
enzymatic control, rather than chromatin marks that 
could only be changed by histone replacement. Th  e 
activity of the LSD1–CoREST–HDAC complex has been 
implicated in tumori  genesis. A recent study using ELISA 
determined that LSD1 is highly expressed in ER-negative 
breast tumors, and hence LSD1 was suggested to serve as 
a predictive marker for aggressive breast tumor biology 
and a novel attractive therapeutic target for treatment of 
ER-negative breast cancers [35]. In ER-positive human 
breast cancer MCF-7 cells, 42% and 58% of all Pol II and 
ERα-bound promoters, respectively, were found to be 
bound by LSD1, and the recruitment of LSD1 to the 
promoters of LSD1+/ERα+ target genes was stimulated by 
estradiol [36].
Intriguingly, Perillo and colleagues reported that LSD1-
mediated demethylation produces H2O2, which subse-
quently modiﬁ   es the surrounding DNA  and recruits 
8-oxoguanine-DNA glycosylase 1 and topoisomerase IIβ, 
triggering conformational changes in DNA and chroma-
tin that are essential for estrogen-induced transcription 
[37]. Our recent study demonstrated that LSD1 interacts 
closely with HDACs in human breast cancer cells. 
Importantly, inhibitors of histone demethylation and 
deacety  lation exhibit cooperation and synergy in regulat-
ing gene expression and growth inhibition, and may 
represent a promising and novel approach for epigenetic 
therapy of breast cancer [38]. Recent studies also revealed 
that LSD1 is able to demethylate nonhistone substrates 
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functions for LSD1 [39,40].
Subsequent to the discovery of LSD1, other Jumonji C 
(JmjC) domain-containing proteins were proposed to 
function as human histone demethylases. Th  ese  enzymes 
use α-ketoglutarate and iron as cofactors to demethylate 
histone lysine residues through a hydroxylation reaction 
[41-44]. Little is known about the role of JmjC domain-
containing histone demethylase in breast cancer, but 
recent studies found that PLU-1 (also known as JARID1B 
or KDM5B) contributes to MCF-7 cell proliferation by 
facilitating G1 progression. Further, knockdown of PLU-1 
led to a signiﬁ  cant reduction of MCF-7 cell proliferation 
and upregulation of expression of certain tumor suppres-
sor genes, including 14-3-3σ, BRCA1, CAV1, and 
HOXA5 [45]. Sharma and colleagues reported that the 
development of drug-tolerant cancer cells was at least in 
part mediated by activities of the histone demethylase 
JARID1A/KDM5A. While these studies focused on epi-
dermal growth factor receptor-targeting small-molecule 
inhibitors in lung cancer cells, the authors showed that a 
similar mechanism for resistance existed for other thera-
pies, such as cis-platin. One could thus rationalize that 
activation of this pathway might be a more widespread 
phenomenon for the development of drug resistance in 
JARID1A/KDM5A-expressing tumors [46,47].
Emerging therapeutic potential of histone 
methyltransferase and demethylase inhibitors in breast 
cancer
As depicted in Figure 2, histone methylation is the result 
of a dynamic equilibrium between activities of a number 
of histone methyltransferases and demethylases. Given 
the increasing evidence for their role in tumorigenesis, it 
is no surprise they are being developed and tested as 
novel treatment targets.
Enhanced activity of histone-modifying enzymes such 
as LSD1 and EZH2 leads to epigenetic silencing of critical 
genes, such as tumor suppressor genes, that have been 
shown to play an important role in breast tumor 
tumorigenesis. A series of novel compounds function as 
powerful inhibitors of histone methylation or demethy  la-
tion and are capable of inducing re-expression of 
aberrantly silenced genes important in breast tumori-
genesis. A list of identiﬁ  ed histone methyltransferase and 
demethylase inhibitors is presented in Table 1. One of the 
ﬁ   rst histone methyltransferase inhibitors developed is 
chaetocin, which exhibits some selectivity for the SUV39 
class of histone methyltransferases [48]. Th  e EZH2 
inhibitor DZNep induces robust apoptosis in breast 
cancer cells, at least in part by including a novel apoptosis 
eﬀ   ector, FBXO32 [49]. SMYD3 is a H3K4-speciﬁ  c 
methyltransferase that is frequently overexpressed in a 
Figure 2. Model of dynamic interplay of enzymes mediating methylation of histone lysines. Methylases are shown in pink and demethylases 
are shown in brown.
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Page 4 of 11variety of cancers, includ  ing breast cancer [50]. 
Novobiocin, known as a HSP90 inhibitor, decreases the 
expression of SMYD3 and inhibits the proliferation and 
migration of MDA-MB-231 cells in a dose-dependent 
fashion [51].
Th  e structural and catalytic similarities of LSD1 and 
monoamine oxidase or polyamine oxidase provided the 
rationale to investigate whether existing monoamine 
oxidases or polyamine oxidase inhibitors might also act 
as inhibitors of LSD1. Subsequently, the monoamine 
oxidase inhibitors tranylcypromine, clorgyline, and 
pargyline were shown to inhibit LSD1 activity and inhibit 
growth of breast cancer and prostate cancer cells 
[35,52,53]. Interestingly, pargyline (Eutonyl; Sigma-
Aldrich, St Louis, MO, USA) has already been clinically 
used for the treatment of vascular hypertension, and 
tranylcypromine (Parnate; Sigma-Aldrich, St Louis, MO, 
USA) is a drug used as an antidepressant and anxiolytic 
agent in the clinical treatment of mood and anxiety 
disorders. Unless there are toxicities due to the high 
doses that might be required to inhibit LSD1, one might 
expect this drug to be tested in the cancer arena soon.
More recently, polyamine-based LSD1 inhibitors were 
identiﬁ   ed and demonstrated to reactivate epigenetic-
silenced tumor suppressor genes in cancer cells [54,55]. 
Treatment with the LSD1-inhibiting polyamine ana-
logues 2d or PG-11144 signiﬁ   cantly enhanced global 
H3K4me2 and altered gene expression in breast cancer 
MDA-MB-231 cells [56]. Treatment with the LSD1 
inhibitor PG-11144 and the DNMT inhibitor 5-aza-2-
deoxycytidine resulted in signiﬁ  cant inhibition of the 
growth of established tumors in a xenograft model of 
human colon cancer in nude mice [55]. N-oxalylglycine, 
an analog of α-keto  glutarate, has been shown to be an 
inhibitor of the JmjC domain-containing histone 
demethylases JMJD2A and JMJD2C [57]. Th  ese 
advances show the promise of using novel compounds 
that target the histone methylation/demethylation 
pathway as an innovative approach to breast cancer 
treatment, and are anticipated to lead to the 
development of a new generation of therapeutically 
eﬀ  ective epigenetically-active drugs with considerable 
clinical potential.
The DNA epigenome in breast cancer
Single-marker studies in breast cancer
Over the past decade, signiﬁ  cant progress has been made 
in the identiﬁ  cation and characterization of altered DNA 
methylation in breast cancer development and progres-
sion. A number of genes have been consistently reported 
to be methylated, including RASSF1A, ERα, PR, RARβ, 
CCND2, and PITX2. We will not review these ﬁ  ndings 
here, but would like to point the interested reader 
towards a number of comprehensive reviews on this 
topic [20,58,59]. Th  e other frequently hyper  methylated 
gene with a tumor-speciﬁ  c methylation proﬁ  le is BRCA1 
[60,61]. Although it has become clear that inactivation of 
BRCA1 by epigenetic means is a critical event in breast 
(and ovarian) tumorigenesis, diﬀ  er  ences in experimental 
approaches and also in the region of the BRCA1 
promoter analyzed resulted in ranges of methylation, and 
thus warrant some further analysis. In any case, in the 
present review we will focus on results from some recent 
genome-wide methylation studies in breast cancer.
Analysis of the breast cancer epigenome using genome-
wide approaches
Unprecedented advances have been made in the develop-
ment of techniques to study genome-wide DNA methy  la-
tion. Brieﬂ  y, there are currently four major approaches to 
identify 5-methylcytosine: restriction endonuclease-
based analysis, bisulﬁ  te-conversion of DNA, aﬃ   nity and 
immunoprecipitation-based studies (methyl Cp6 binding 
domain (MBD) pulldown, or antibodies against 
5-methylcytosine in DNA or against proteins binding to 
5-methylcytosine, such as MBD2 and MeCP2), and 
ﬁ   nally mass spectrometry-based analysis. Most of the 
approaches have been adapted to be used for genome-
wide studies using array-based or sequencing-based 
methods, and some have been utilized to study 
methylation of the breast cancer genome, as discussed 
below.
In 2007 Ordway and colleagues used cytosine methy-
lation-dependent restriction enzyme McrBC coupled 
with array hybridization to analyze methylation in nine 
matched invasive ductal carcinoma and adjacent normal 
tissue [62]. Th  ey identiﬁ  ed 220 diﬀ  erentially methylated 
Table 1. Characteristics of some histone methyltransferase and demethylase inhibitors
Inhibitor  Major targeted enzymes  Changed histone marks  Citation
Chaetocin1 Suv39h1,  G9a  H3K9  [48]
DZNep EZh2  H3K27  [49]
Novobiocin SMYD3  H3K4  [51]
Trancylpromine, clorgyline, pargyline  LSD1, LSD2  H3K4, H3K9  [35,52,53]
Polyamine analogs  LSD1  H3K4  [54,55]
N-oxalylglycine  JMJD2A, JMJD2C  H3K9, H3K36  [57]
Huang et al. Breast Cancer Research 2011, 13:225 
http://breast-cancer-research.com/content/13/6/225
Page 5 of 11loci, and analyzed 16 genes that were able to diﬀ  erentiate 
breast tumor from normal and benign tissues and blood 
in more detail. One of these genes was GHSR, a member 
of the G-protein-coupled receptor that binds to ghrelin. 
Methylation of GHSR was able to diﬀ  erentiate invasive 
ductal carcinoma from normal or benign breast tissue 
with high speciﬁ  city and sensitivity. Th   e same group went 
on to study four of the highly methylated loci – GHSR, 
max gene-associated, nuclear factor I/X, and an un-
annotated region on chromosome 7 – in more detail 
through bisulﬁ   te pyrosequencing using DNA from 
breast tumors, normal breast, and sera from cancer 
patients and from normal controls. Disappointingly, no 
tumor-speciﬁ  c methylation pattern could be identiﬁ  ed, 
and high methy  la  tion rates were detected in normal sera 
[63]. Th  e latter would clearly pose a problem for the 
development of sera-based assays and highlights the 
need to identify markers that are not methylated in 
normal serum.
Ruike and colleagues reported results from a genome-
wide methylated DNA immunoprecipitation-sequencing 
study in breast cancer cells [64]. Brieﬂ  y, they identiﬁ  ed 
methylated DNA in eight breast cancer cell lines and one 
normal breast cell line, and in addition they compared 
methylation rates between parental MCF-7 cells and 
MCF-7 cells that had undergone epithelial to mesen-
chymal transition. As expected, the cancer cell lines were 
characterized by global hypomethylation, concurrent 
with hypermethyla  tion of many loci. Th  e hypomethy-
lation, which was distributed throughout the entire 
genome, was three to ﬁ   ve times more frequent than 
hypermethylation, which was clustered at speciﬁ  c loci. 
Intriguingly, 53% of methylated CpG was found outside 
CpG islands. Of interest was also the association of 
epithelial to mesenchymal transition with hypomethyla-
tion at many CpG islands, a ﬁ   nding that deserves 
follow-up.
It will be of great value to apply these approaches to 
answer clinical questions, such as the association of 
genome-wide changes in DNA methylation with diﬀ  erent 
grades or stages of breast tumor. A recent genome-wide 
study by Fang and colleagues [65] has suggested that a 
CpG island methylator phenotype (CIMP) exists in breast 
cancer. Th  is breast cancer CIMP provided a distinct 
epigenomic proﬁ  le, which was associated with genes that 
make up the metastasis transcriptome. Additional studies 
need to be performed before one can conﬁ  dently state 
that there are CIMP tumors associated with speciﬁ  c 
tumor phenotypes. Another interesting question is the 
association between methylation and molecular subtypes 
of breast tumors.
A recent study by Holm and colleagues suggests that 
luminal tumors have higher frequencies of methylation 
compared with basal or triple-negative breast tumors 
[58]. Brieﬂ   y, the authors studied 189 frozen primary 
breast tumors using the Illumina Golden Gate Methy-
lation Cancer Panel, covering 1,505 CpG loci in 807 
cancer-related genes. Unsupervised clustering revealed 
that methylation patterns were associated with luminal 
A, luminal B, and basal-like tumors, with luminal B 
tumors being most methylated and basal-like tumors 
being the least methylated. As previously reported, Her-2 
tumors are very heterogeneous and are mainly driven by 
ampliﬁ   cation of Her-2 as the common denominator. 
High expression of PRC2 and low methylation of known 
PRC2 targets in basal-like tumors suggest that PRC2 
targets might be silenced by trimethylation of H3K27 in 
this tumor subset. In general, these data clearly suggest 
that methylation plays a signiﬁ  cant role in the diﬀ  erent 
breast tumor subsets, and it will be critical to determine 
the mechanism that drives diﬀ  erent methylation states. 
Th  e authors speculate a role for genetic changes in 
methylation enzymes, an interesting hypothesis that is 
testable.
Lineage-speciﬁ   c methylation was also observed in a 
methylation study performed by Sproul and colleagues 
[66], who used 27K Inﬁ  nium arrays to study the methy-
lation at >14,000 genes in 19 breast cancer cell lines and 
47 primary tumors. Th   e authors bring forward the argu-
ment that DNA methylation in breast tumors is a marker 
of cell lineage rather than tumor progression. Th  is  study 
again emphasizes the need to identify tumor-speciﬁ  c 
methylation events, a task most critical for the future use 
of DNA methylation for diagnosis and treatment of 
breast cancer.
Another clinical question is the involvement of DNA 
methylation in the adaptation of cancer cells to treatment 
exposure. We recently performed an MBD-pulldown 
assay in breast cancer cells deprived of estrogen, thus 
mimicking treatment with aromatase inhibitors. Th  is 
approach resulted in the identiﬁ  cation of a large number 
of hypermethylated genes, and fewer that were 
hypomethylated (Pathiraja and colleagues, manuscript in 
preparation). It will be of great interest to expand those 
studies to clinical samples, in order to identify markers of 
resistance, and potential drug targets.
Clearly, these studies are only the beginning for the use 
of genome-wide methylation studies. With the advent of 
improved technologies, we should expect to witness an 
explosion of studies aimed at understanding epigenetic 
changes in breast cancer. Th  is not only refers to DNA 
methylation, but also to other epigenetic changes, such as 
histone modiﬁ   cation, which can now also be studied 
genome wide through the use of chromatin immuno-
precipitation technologies At least in part, these eﬀ  orts 
should soon beneﬁ   t from the results of the Human 
Epigenome Project and TCGA, as brieﬂ  y  discussed 
below.
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understanding epigenetics of breast cancer 
(and other diseases)
Description of Epigenome Roadmap initiatives
Th  e Epigenome Project is a Roadmap initiative led by 
several National Institutes of Health (NIH) centers, 
started in 2008 when the NIH decided to invest over $190 
million to accelerate the advancement of biomedical 
research in epigenomics. A series of ﬁ  ve initiatives was 
therefore created. Th  e ﬁ  rst initiative is the creation of 
reference epigenome mapping centers, which support the 
development of reference epigenomes of a variety of 
human cells, including normal breast epithelial cells. Th  e 
data gathered include information on DNA methylation, 
histone modiﬁ  cations, and associated noncoding RNAs. 
Th  e second initiative focuses not only on coordinating 
the banking of data, but also on facilitating its access to 
the public, accomplished through the creation of the 
Epigenomic Data Analysis and Co  ordination center. Th  e 
third initiative seeks to advance technology in epigenetic 
research, by enabling the development of new techniques, 
including the creation of methods that allow in vivo 
imaging of epigenetic changes. Th  e objective of the 
fourth initiative is to identify epigenetic marks and 
establish their function in mammalian cells. Finally, the 
intention of the ﬁ   fth initiative is to identify those 
epigenetic changes that are the cause of speciﬁ  c diseases, 
including breast cancer.
Importantly, the NIH roadmap initiative is part of an 
international association, the International Human Epi-
genome Consortium, which has made several recom-
mendations with regard to data release, format, and 
various technical considerations, in order to universalize 
and validate ﬁ   ndings [67]. Regarding the former, it is 
recommended that all data be made available through 
one of several public databases, such as GEO, 
ARRAYEXPRESS, and DDBJ.
Funded roadmap initiatives have resulted in many 
fundamental contributions, including a study published 
late in 2009 that presented the ﬁ  rst genome-wide, single-
base resolution map of methylated cytosines in the 
mammalian genome from both human embryonic stem 
cells and fetal ﬁ  broblasts [68]. Importantly, almost one-
quarter of all methylation identiﬁ  ed in stem cells was in a 
non-CpG context, a ﬁ  nding that does not seem to be 
restricted to methylation in stem cells. Subsequently, an 
approach was developed to sequence chromatin-immuno-
precipitated DNA from limited cell populations, an 
approach most critical for working with clinical samples 
[69]. A study by Ernst and Kellis described a multivariate 
Hidden Markov Model to reveal chromatin states in 
human T cells through the systematic analysis of 51 
chromatin states, including promoter-associated states, 
transcription-associated states, active intergenic states, 
large-scale repressed states, and repeat-associated states 
[70].
Finally, two studies have explored the strengths and 
weaknesses of four methods of DNA methylation 
mapping technologies, while providing recommendations 
on the design of case–control studies in epigenomics 
[71,72]. Th  ese studies mark a critical milestone for the 
Human Epigenome Project, since the development of 
genome-wide tech  nology has been a major focus on the 
initiative. Brieﬂ  y, six methods were tested, of which ﬁ  ve 
were sequence-based and one was array-based. Each 
method was subjected to rigorous testing, and to 
statistical analysis of at least two replicate samples. 
Although resolution and coverage diﬀ   ered, there was 
high concordance between the diﬀ  erent  methods, 
providing a high level of con  ﬁ   dence for all epigenetic 
researchers, and providing ﬂ  exibility as to which methods 
to choose based on the need for resolution, the amount 
of available starting material, and, last but not least, the 
budget.
NIH Roadmap studies deciphering the breast cancer 
epigenome
Th   e initiative also funded disease-speciﬁ  c studies, includ-
ing those in breast cancer. One such study is the analysis 
of special AT-rich sequence binding 1 (SATB1) in 
metastatic breast cancer. Th   e Kohwi-Shigematsu labora-
tory identiﬁ  ed SATB1, originally described as a genome 
organizer in thymocytes [73-75], to be a key deter  minant 
in breast cancer metastasis [76].
While there is some controversy about the detailed 
function of SATB1 in breast cancer [77], there is no 
doubt that SATB1 functions as a critical, global, genome 
organizer by recognizing and binding to specialized DNA 
sequences in the genome that have a high propensity to 
unwind (base-unpairing regions). SATB1 organizes 
chromatin into loops through binding of base-unpairing 
regions, which are found in gene-rich regions, and can 
regu  late a large number of distally located genes by 
functioning as a landing platform for multiple chromatin 
remodeling/modifying proteins that confer speciﬁ  c 
epigenetic marks [78]. In breast cancer, once SATB1 
becomes expressed, it regulates ~1,000 genes, including 
those involved in cancer progression, metastasis, and 
growth (for example, ERBB2, transforming growth factor 
beta).
Th   e Kohwi-Shigematsu group is currently using 
genome-wide approaches to map all base-unpairing 
regions in the genome and to determine which particular 
subset of these is bound by SATB1, and whether these 
speciﬁ   c epigenomic modiﬁ   cations are associated with 
poor-prognosis expression proﬁ  les of aggressive breast 
cancers. In addition, using a new approach of analyzing 
three-dimensional gene interactions, they have found 
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close proximity with a multitude of genes related to myc 
or co-ampliﬁ  ed in cancer. Forced SATB1 expression in 
nonaggressive breast cancer cells led to a major change in 
c-MYC interaction pattern, establishing new connections 
with genes, some of which are related to cancer 
(T  Kohwi-Shigematsu, personal communication). Th  is 
study provides a concrete example of how the Epigenome 
Project supports the understanding of the progression 
from nonaggressive breast cancer to metastatic cancer by 
establishing genome-wide changes in epigenetic marks, 
at least in part through global reorganization of higher 
order chromatin structures by proteins such as SATB1 
and others. Th  e critical role for chromatin-organizing 
proteins is reﬂ  ected by frequent mutations, such as the 
recently described mutation of ARID1A in ovarian 
cancer [47] and other cancers [79].
In addition, beginning in October 2010, the Epigenome 
Project began to release data that included more than 300 
maps of epigenetic changes in over 56 cell and tissue 
types, including a number of normal breast cells [80]. For 
example, one can access data on DNA methylation as 
well as a number of critical genome-wide histone markers 
(for example, methylation at lysines K4, K9, K27, and 
K36). Th  ese data should help to deﬁ  ne breast cancer-
speciﬁ  c changes, by allowing researchers to compare the 
breast cancer data with the normal reference epigenome. 
Th  is, however, brings up one of several hurdles the 
project must overcome. Th  ere are challenges regarding 
data integration, interpretation, and dissemination – as 
one would expect given that the technologies used are all 
relatively new. Th   ere is a critical need for the creation of a 
new generation of tools for interpretation of the 
numerous epigenetic datasets [81]. Brieﬂ  y, in contrast to 
DNA sequence data, epigenomic data are not digital, 
diﬀ   er in resolution, and are highly variable. Th  ese 
features make comparisons of epigenomes challenging, 
and require sophisticated informatics tools often not 
easily accessible for just any general laboratory. 
Increasing accumulation of data, coupled with improved 
data and tool integration, and access to computing 
resources and services, preferably through well-estab-
lished and proven pipelines, are necessary for the eﬃ   cient 
and successful analysis of the unprecedented increase of 
epigenetic information.
Epigenetic studies in breast cancer as part of The Cancer 
Genome Atlas
TCGA began in 2006 as a combined eﬀ   ort by the 
National Cancer Institute and the National Human 
Genome Research Institute. Th   e success of the three-year 
pilot project led the NIH to commit major resources to 
TCGA to collect and characterize more than 20 tumor 
types, including breast cancer. Tumor DNA and RNA will 
be thoroughly characterized using a number of 
approaches. Data are currently available for the brain 
tumor glioblastoma multiforme (GBM) and ovarian 
cancer, and we can expect more completion of the breast 
cancer studies by the end of this year.
Currently, epigenomics studies within TCGA use the 
HumanMethylation27 BeadChip (Illumina, San Diego, 
CA, USA). Th   is assay allows quantitative interrogation of 
27,578 CpG loci covering more than 14,000 genes at 
single-nucleotide resolution. Speciﬁ   cally, the panel 
targets CpG sites located within the proximal promoter 
regions of 14,475 consensus coding sequences, and in 
110 miRNA pro  moters. As of April 2011 these data have 
been available from the TCGA data portal for more than 
400 breast cancers [82], and we can look forward to the 
report of its ﬁ   rst analysis. Of note, a similar TCGA-
directed approach in GBM resulted in the identiﬁ  cation 
of a unique glioma CIMP in about 10% of patients, who 
are usually very young at the time of diagnosis. Th  ese 
patients survive more than 3  years, which is in stark 
contrast to most GBM patients who survive fewer than 
15 months. Interestingly, the study also revealed an asso-
ciation between glioma CIMP with an acquired mutation 
in the IDH1 gene.
Th   e development of these technologies is moving very 
rapidly, and just when we thought we had a battery of 
gold standards for genome-wide analysis of DNA methy-
la  tion it becomes clear that additional modiﬁ    cations such 
as hydroxymethyl cytosines, and methylated cytosines 
outside mCpG islands and outside promoter regions, are 
likely to play critical roles, including in breast cancer. 
One may have speculated that the sole analysis of 
promoter methylation – as done in the TCGA studies – 
might miss cancer-speciﬁ   c changes in other critical 
regulatory regions. Th   e exciting ﬁ  ndings from the GBM 
study, however, clearly show that promoter methylation 
includes clinically signiﬁ  cant information, and we should 
look forward to additional data and analyses from the 
breast cancer TCGA studies.
Conclusions
While an understanding of epigenetic changes in breast 
cancer has yet to be translated into clinical care, we 
should expect major steps forward over the next few 
years. Fundamental discoveries in the understanding of 
basic epigenetic regulatory mechanisms and dramatic 
advances in powerful technologies, together with large 
national and international epigenome projects, will 
enable identiﬁ  cation of breast cancer-speciﬁ  c alterations, 
and thus potential predictive markers and treatment 
targets. We ﬁ   rmly believe we have entered an era of 
epigenomics that will bring beneﬁ   ts for breast cancer 
patients.
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